Jason Gerberry
Stock Analyst at B of A Securities
(4.28)
# 388
Out of 5,182 analysts
169
Total ratings
62.4%
Success rate
11.29%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $38 → $42 | $31.29 | +34.23% | 16 | Apr 9, 2026 | |
| PFE Pfizer | Maintains: Neutral | $27 → $26 | $27.31 | -4.80% | 6 | Apr 9, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $100 → $111 | $74.78 | +48.44% | 8 | Apr 9, 2026 | |
| ALKS Alkermes | Maintains: Neutral | $34 → $36 | $33.52 | +7.40% | 11 | Apr 9, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,293 → $1,294 | $903.02 | +43.30% | 16 | Apr 2, 2026 | |
| LENZ LENZ Therapeutics | Maintains: Buy | $35 → $29 | $9.87 | +193.82% | 1 | Mar 25, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $263 → $275 | $199.03 | +38.17% | 7 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Underperform | $32 → $28 | $32.14 | -12.88% | 3 | Feb 25, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $71.05 | +14.00% | 4 | Dec 9, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $27.38 | +5.92% | 4 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $32 | $21.21 | +50.87% | 2 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $28.28 | +6.08% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $49 | $10.19 | +380.86% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $173 → $176 | $182.97 | -3.81% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $2.09 | -52.15% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $36.25 | -36.55% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $45.89 | +0.24% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $60.55 | +126.26% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $14.73 | -32.11% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $25.64 | +17.00% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $114.98 | -13.03% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $16.80 | +42.86% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $28.93 | +7.16% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $56.40 | -0.71% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.32 | +287.93% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $8.84 | +182.81% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.74 | +187.36% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.73 | +371.20% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.82 | +998.90% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $6.32 | +1,482.28% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $205.12 | -53.69% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $59.39 | +1.03% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $112.56 | -20.04% | 11 | Oct 17, 2019 |
Teva Pharmaceutical Industries
Apr 9, 2026
Maintains: Buy
Price Target: $38 → $42
Current: $31.29
Upside: +34.23%
Pfizer
Apr 9, 2026
Maintains: Neutral
Price Target: $27 → $26
Current: $27.31
Upside: -4.80%
Ionis Pharmaceuticals
Apr 9, 2026
Maintains: Buy
Price Target: $100 → $111
Current: $74.78
Upside: +48.44%
Alkermes
Apr 9, 2026
Maintains: Neutral
Price Target: $34 → $36
Current: $33.52
Upside: +7.40%
Eli Lilly and Company
Apr 2, 2026
Maintains: Buy
Price Target: $1,293 → $1,294
Current: $903.02
Upside: +43.30%
LENZ Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $35 → $29
Current: $9.87
Upside: +193.82%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $263 → $275
Current: $199.03
Upside: +38.17%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Underperform
Price Target: $32 → $28
Current: $32.14
Upside: -12.88%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $71.05
Upside: +14.00%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $27.38
Upside: +5.92%
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $21.21
Upside: +50.87%
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $28.28
Upside: +6.08%
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $10.19
Upside: +380.86%
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $182.97
Upside: -3.81%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.09
Upside: -52.15%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $36.25
Upside: -36.55%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $45.89
Upside: +0.24%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $60.55
Upside: +126.26%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $14.73
Upside: -32.11%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $25.64
Upside: +17.00%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $114.98
Upside: -13.03%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $16.80
Upside: +42.86%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.93
Upside: +7.16%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $56.40
Upside: -0.71%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.32
Upside: +287.93%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $8.84
Upside: +182.81%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.74
Upside: +187.36%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.73
Upside: +371.20%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.82
Upside: +998.90%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $6.32
Upside: +1,482.28%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $205.12
Upside: -53.69%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $59.39
Upside: +1.03%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $112.56
Upside: -20.04%